HAMILTON, Bermuda, July 18, 2016 /PRNewswire/ -- Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, announced today that the company will host a symposium and make four poster presentations at the 2016 Alzheimer's Association International Conference (AAIC) being held in TorontoJuly 24-28.
"Our presence at this year's AAIC highlights our progress towards building a leading pipeline of potential treatments for patients with dementia," said Vivek Ramaswamy, CEO of Axovant Sciences. "Over the next 18 months, we expect to report results from all four of our ongoing studies in both Alzheimer's disease and Lewy body dementia. If developed successfully, our pipeline of innovative CNS product candidates will have the opportunity to improve the lives of millions of patients and their families."
During the conference, Axovant is sponsoring a symposium entitled "The Debate Continues: Unraveling the Science of Alzheimer's Disease," featuring two clinical debates involving the following speakers: Lon S. Schneider, MD, Dennis J. Selkoe, MD, Rachelle S. Doody, MD, PhD, Khalid Iqbal, PhD, and Gary Small, MD (moderator).
In addition, Peter Mittler, CBE, PhD, a trained clinical psychologist who has devoted his career to championing the rights of people with intellectual and developmental disabilities to education and citizenship and recently addressed the United Nations regarding dementia treatment as a human rights issue, will deliver a keynote address "Living Well with Dementia: A Fundamental Human Rights Issue."
Symposium
The Debate Continues: Unraveling the Science of Alzheimer's Disease
Date: Wednesday, July 27, 2016 6:00 P.M. 8:45 P.M. EDT
Location: Fairmont Royal York Hotel
The company will present the following posters:
A Large, Randomized, DoubleBlind, PlaceboControlled Study Evaluating Intepirdine (RVT-101), a NeurotransmitterTargeted Therapy, in Subjects with MildtoModerate Alzheimer's Disease on Donepezil Treatment: Phase 3 MINDSET Study Design
Date: July 27, 2016 9:30 A.M. 10:30 A.M. EDT
Location: Metro Toronto Convention Centre Room Hall D/E
Abstract Number: P4-001
In Vivo Alterations in Brain Glucose Utilization with Intepirdine (RVT-101), a 5-HT6 Receptor Antagonist for the Treatment of Alzheimer's Disease
Date: July 27, 2016 9:30 A.M. 10:30 A.M. EDT
Location: Metro Toronto Convention Centre Room Hall D/E
Abstract Number: P4-022
Effect of Food on the Pharmacokinetics of Intepirdine (RVT-101) in Healthy Adult Subjects
Date: July 26, 2016 9:30 A.M. 10:30 A.M. EDT
Location: Metro Toronto Convention Centre Room Hall D/E
Abstract Number: P3-014
An Evaluation of the Safety in Human Subjects of Nelotanserin, a Highly Potent and Selective 5HT2A Inverse Agonist Being Developed as a Treatment for Visual Hallucinations and REM Behavior Disorder in Lewy Body Dementia
Date: July 26, 2016 9:30 A.M. 10:30 A.M. EDT
Location: Metro Toronto Convention Centre Room Hall D/E
Abstract Number: P3-018
About Axovant
Axovant Sciences Ltd. is a leading clinical-stage biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutics for the treatment of dementia. Axovant intends to develop a pipeline of product candidates to comprehensively address the cognitive, behavioral and functional components of dementia and related neurological disorders. Our vision is to become the leading company focused on the treatment of dementia by addressing all forms and aspects of the condition.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/axovant-sciences-announces-presentations-and-sponsored-symposium-at-the-2016-alzheimers-association-international-conference-300300184.html
SOURCE Axovant Sciences Ltd.
